fromSilicon Canals1 week agoDutch-based Azafaros raises 132MAzafaros has been impressive in its execution with nizubaglustat poised to begin Phase 3 clinical development and the potential to significantly improve the lives of NPC and GM1/GM2 patients.Startup companies